Median Technologies

(Booth 8548) French CAD software developer Median Technologies will appear at its first RSNA conference since receiving U.S. Food and Drug Administration clearance for CAD offerings for lung and liver imaging in its Lesion Management Solutions (LMS) line of software.

Median's LMS-Lung/Track and LMS-Liver applications are designed to assist radiologists in all aspects of diagnosing and tracking lesions, from lesion measurement to generating follow-up reports. The software measures key lesion characteristics, such as volume and longest axial diameters, and pairs the lesions in follow-up exams, computing their growth and doubling time. Reports can also be generated according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria used in oncology to assess the treatment response of solid tumors, according to the company.

Both LMS-Lung/Track and LMS-Liver support images acquired on any multislice CT scanner, and can be integrated with modality or PACS/RIS workstations. LMS-Lung/Track was cleared in May 2007, while LMS-Liver received clearance a month later. The company is shipping LMS software in 15 countries in Europe, and expects to begin commercial sales in the U.S. in coming months.